HER2 + Breast Cancer Clinical Trials

8 recruiting

HER2 + Breast Cancer Trials at a Glance

8 actively recruiting trials for her2 + breast cancer are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Nashville, Milan, and Ann Arbor. Lead sponsors running her2 + breast cancer studies include Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Iambic Therapeutics, Inc, and Affibody.

Browse her2 + breast cancer trials by phase

Treatments under study

About HER2 + Breast Cancer Clinical Trials

Looking for clinical trials for HER2 + Breast Cancer? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2 + Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2 + Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 2Phase 3

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

HER2 + Breast Cancer
Shanghai Henlius Biotech706 enrolled1 locationNCT07294508
Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Breast CancerTNBC - Triple-Negative Breast CancerEarly Stage Breast Cancer+2 more
Tempus AI900 enrolled12 locationsNCT07211178
Recruiting
Phase 2

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

HER2 + Breast Cancer
Shanghai Jiao Tong University School of Medicine50 enrolled1 locationNCT07393425
Recruiting
Phase 1

A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

Metastatic Breast CancerHER2 + Breast Cancer
Affibody21 enrolled3 locationsNCT07081555
Recruiting

HER2-positive Breast Cancer Registry

HER2 + Breast Cancer
Priyanka Sharma1,000 enrolled6 locationsNCT06603597
Recruiting
Phase 2

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

HER2 + Breast Cancer
The First Affiliated Hospital with Nanjing Medical University74 enrolled1 locationNCT07065435
Recruiting

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Breast CancerBreast Cancer MetastaticBreast Carcinoma+9 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano500 enrolled1 locationNCT07030569